IBOV 177,284 ▼ 0.61% IPSA 10,421 ▼ 0.58% IPC MEX 67,977 ▼ 1.78% MERVAL 2,707,869 ▼ 1.44% COLCAP 2,118 ▼ 0.22% BVL PERÚ 19,767 ▲ 0.37% USD/BRL 5.05 ▼ 0.01% USD/MXN 17.33 ▲ 0.10% USD/CLP 908.88 ▲ 1.38% USD/COP 3,791 ▲ 0.09% USD/PEN 3.43 ▼ 0.01% USD/ARS 1,395 — 0.00% USD/UYU 40.07 ▲ 1.92% USD/PYG 6,066 ▲ 1.38% USD/BOB 6.86 ▲ 1.77% USD/DOP 59.15 ▼ 0.50% USD/CRC 451.24 ▲ 1.80% USD/GTQ 7.62 ▲ 2.19% USD/HNL 26.61 ▲ 0.29% USD/NIO 36.62 ▲ 0.26% USD/VES 513.89 ▼ 0.66% USD/PAB 1.00 ▲ 2.16% USD/BZD 2.00 ▲ 1.59% USD/JMD 157.28 ▲ 0.43% USD/TTD 6.74 ▲ 1.22% EUR/BRL 5.89 ▲ 0.19% BRENT 109.26 ▲ 3.35% WTI 101.02 ▼ 0.15% IRON ORE 161.91 — — COPPER 6.30 ▼ 4.15% GOLD 4,562 ▼ 2.48% SILVER 77.55 ▼ 8.67% SOY 1,177 ▲ 0.21% CORN 455.75 ▲ 0.94% WHEAT 635.75 ▼ 1.74% COFFEE 258.75 ▼ 12.12% SUGAR 14.78 ▼ 1.40% ORANGE JUICE 170.05 ▼ 6.21% COTTON 80.33 ▼ 4.30% COCOA 4,109 ▼ 1.91% BEEF 247.93 ▼ 1.65% CATTLE 361.45 ▼ 1.67% LITHIUM 84.08 ▼ 3.30% PETR4 45.47 ▲ 1.04% VALE3 83.50 ▲ 0.76% ITUB4 39.70 ▼ 1.73% BBDC4 17.69 ▼ 0.84% ABEV3 15.69 ▼ 0.51% BBAS3 20.70 ▼ 0.29% B3SA3 16.70 ▼ 1.36% WEGE3 43.13 ▼ 1.35% PRIO3 68.80 ▲ 2.24% SUZB3 41.70 ▼ 2.16% RENT3 42.98 ▼ 2.18% AZZA3 19.05 ▲ 1.06% CSAN3 4.41 ▼ 5.16% RAIZ4 0.45 ▲ 2.27% PCAR3 2.26 ▼ 1.74% GMAT3 4.34 ▲ 1.17% PSSA3 47.92 ▼ 1.60% CVCB3 1.81 ▼ 4.23% POSI3 3.88 ▼ 2.27% SLCE3 17.19 ▼ 0.87% NATU3 9.94 ▲ 1.53% BRKM5 12.21 ▲ 0.49% RANI3 7.85 ▼ 0.25% CSNA3 6.42 ▼ 3.75% CMIN3 4.72 ▼ 1.05% USIM5 9.12 ▼ 7.79% GGBR4 23.34 ▼ 1.02% ENEV3 25.06 ▼ 3.43% NEOE3 33.80 — 0.00% CPFE3 44.52 ▼ 1.53% CMIG4 11.27 ▼ 0.09% EQTL3 38.59 ▼ 0.54% LREN3 13.55 ▼ 1.24% VIVT3 35.52 ▼ 0.20% RAIL3 14.97 ▼ 1.96% KLABIN 16.43 ▼ 2.55% RAIA DROGASIL 19.59 ▼ 0.25% RDOR3 34.84 ▲ 0.26% HAPV3 12.45 ▼ 6.11% FLRY3 15.60 ▼ 2.26% SMTO3 18.25 ▼ 0.82% UGPA3 29.13 ▼ 1.42% VBBR3 33.12 ▼ 0.81% BBSE3 34.12 ▼ 1.04% BPAC11 54.50 ▼ 1.61% CURY3 30.37 ▼ 0.75% AERI3 2.42 ▼ 0.41% VIVARA 22.94 ▼ 0.26% COMPASS 25.90 ▼ 1.89% VAMOS 3.41 ▼ 2.29% SANB11 26.92 ▼ 0.81% ASAI3 8.50 ▼ 1.05% SBSP3 29.03 ▼ 1.66% WALMEX 54.82 ▲ 0.53% GMEXICO 202.10 ▼ 4.45% FEMSA 210.39 ▼ 0.01% CEMEX 21.82 ▼ 3.71% GFNORTE 184.04 ▼ 0.98% BIMBO 59.19 ▲ 0.27% TELEVISA 9.94 ▲ 1.43% AMX 23.13 ▼ 1.11% GAP 413.32 ▼ 1.41% ASUR 296.14 ▼ 1.66% OMA 222.96 ▼ 0.70% KOF 180.84 ▼ 0.13% GRUMA 298.23 ▲ 0.12% KIMBER 38.28 ▼ 0.55% SQM-B 76,590 ▼ 2.06% COPEC 6,145 ▼ 0.08% BSANTANDER 68.99 ▼ 0.16% FALABELLA 5,500 ▲ 1.08% ENELAM 75.75 ▼ 0.89% CENCOSUD 2,060 ▼ 3.06% CMPC 1,055 ▼ 0.94% BANCO CHILE 163.70 ▲ 0.13% LATAM AIR 21.54 ▼ 2.53% YPF 65,000 ▼ 0.46% GGAL 6,060 ▼ 2.02% PAMPA 4,720 ▼ 0.26% TXAR 615.00 ▲ 0.49% ALUAR 940.50 ▼ 0.42% TGS 8,750 ▼ 0.62% CEPU 2,049 ▼ 3.17% MIRGOR 17,225 ▼ 3.23% COME 42.52 ▼ 1.51% LOMA NEGRA 3,105 ▼ 1.82% BYMA 272.25 ▼ 2.77% TELECOM ARG 3,505 ▼ 4.24% ECOPETROL 13.11 ▼ 0.87% BANCOLOMBIA 63.16 ▼ 1.83% GRUPO AVAL 4.01 ▼ 5.20% CREDICORP 316.31 ▼ 3.47% SOUTHERN COPPER 176.78 ▼ 6.22% BUENAVENTURA 34.29 ▼ 7.70% MERCADOLIBRE 1,547 ▼ 3.77% NUBANK 12.19 ▼ 5.72% XP 17.47 ▼ 0.74% PAGSEGURO 8.86 ▼ 1.66% STONE 9.61 ▼ 0.93% GLOBANT 38.87 ▲ 14.06% TECNOGLASS 38.61 ▼ 5.90% GAP AIRPORT 238.45 ▼ 2.15% ASUR 296.14 ▼ 1.66% OMA AIRPORT 102.84 ▼ 1.57% AMX ADR 26.59 ▼ 1.85% FEMSA ADR 121.38 ▼ 0.70% CEMEX ADR 12.56 ▼ 4.60% PETROBRAS ADR 19.93 ▲ 0.76% VALE ADR 16.32 ▼ 1.57% ITAU ADR 7.84 ▼ 3.21% SANTANDER BR 5.34 ▼ 2.11% AMBEV ADR 3.07 — 0.00% CSN 1.26 ▼ 6.67% GERDAU 4.61 ▼ 2.12% LATAM ADR 46.91 ▼ 4.79% BTC 78,181 ▼ 1.12% ETH 2,181 ▼ 1.90% SOL 86.83 ▼ 2.66% XRP 1.42 ▼ 1.25% BNB 657.72 ▼ 2.14% ADA 0.26 ▼ 2.29% DOGE 0.11 ▼ 3.47% AVAX 9.34 ▼ 2.06% LINK 9.75 ▼ 3.13% DOT 1.27 ▼ 3.22% LTC 56.17 ▼ 2.30% BCH 417.55 ▼ 2.10% TRX 0.35 ▲ 0.67% XLM 0.15 ▼ 1.56% HBAR 0.09 ▼ 1.23% NEAR 1.50 ▼ 2.83% ATOM 2.01 ▲ 4.10% AAVE 90.55 ▼ 2.47% SELIC 14.50% EMBRAER 71.25 ▼ 1.76% EMBRAER ADR 55.76 ▼ 5.04% JBS 13.48 ▼ 3.58% JBS BDR 68.50 ▼ 1.72% MBRF3 17.42 — 0.00% MBRFY 3.43 ▼ 2.83% INTER 5.85 ▼ 3.47% EGX 53,155 ▼ 0.49% USD/ZAR 16.68 ▲ 1.37% USD/NGN 1,367 ▼ 0.04% NIKKEI 61,409 ▼ 1.99% CSI300 4,860 ▼ 1.12% HSI 25,963 ▼ 1.62% NIFTY 23,644 ▼ 0.19% KOSPI 7,493 ▼ 6.12% JCI 6,723 ▼ 1.98% USD/JPY 158.73 ▲ 0.24% USD/CNY 6.8087 ▲ 0.36% DAX 23,951 ▼ 2.07% CAC 7,953 ▼ 1.60% FTSE 10,195 ▼ 1.71% MIB 49,116 ▼ 1.87% IBEX 17,623 ▼ 1.05% STOXX 606.92 ▼ 1.48% EUR/USD 1.1631 ▼ 0.34% GBP/USD 1.3324 ▼ 0.58% SPX 7,409 ▼ 1.24% DJI 49,526 ▼ 1.07% NDX 29,125 ▼ 1.54% RUT 2,793 ▼ 2.44% TSX 33,833 ▼ 1.27% VIX 18.43 ▲ 6.78% USD/CAD 1.3749 ▲ 0.24% US10Y 4.5950 ▲ 3.00% IBOV 177,284 ▼ 0.61% IPSA 10,421 ▼ 0.58% IPC MEX 67,977 ▼ 1.78% MERVAL 2,707,869 ▼ 1.44% COLCAP 2,118 ▼ 0.22% BVL PERÚ 19,767 ▲ 0.37% USD/BRL 5.05 ▼ 0.01% USD/MXN 17.33 ▲ 0.10% USD/CLP 908.88 ▲ 1.38% USD/COP 3,791 ▲ 0.09% USD/PEN 3.43 ▼ 0.01% USD/ARS 1,395 — 0.00% USD/UYU 40.07 ▲ 1.92% USD/PYG 6,066 ▲ 1.38% USD/BOB 6.86 ▲ 1.77% USD/DOP 59.15 ▼ 0.50% USD/CRC 451.24 ▲ 1.80% USD/GTQ 7.62 ▲ 2.19% USD/HNL 26.61 ▲ 0.29% USD/NIO 36.62 ▲ 0.26% USD/VES 513.89 ▼ 0.66% USD/PAB 1.00 ▲ 2.16% USD/BZD 2.00 ▲ 1.59% USD/JMD 157.28 ▲ 0.43% USD/TTD 6.74 ▲ 1.22% EUR/BRL 5.89 ▲ 0.19% BRENT 109.26 ▲ 3.35% WTI 101.02 ▼ 0.15% IRON ORE 161.91 — — COPPER 6.30 ▼ 4.15% GOLD 4,562 ▼ 2.48% SILVER 77.55 ▼ 8.67% SOY 1,177 ▲ 0.21% CORN 455.75 ▲ 0.94% WHEAT 635.75 ▼ 1.74% COFFEE 258.75 ▼ 12.12% SUGAR 14.78 ▼ 1.40% ORANGE JUICE 170.05 ▼ 6.21% COTTON 80.33 ▼ 4.30% COCOA 4,109 ▼ 1.91% BEEF 247.93 ▼ 1.65% CATTLE 361.45 ▼ 1.67% LITHIUM 84.08 ▼ 3.30% PETR4 45.47 ▲ 1.04% VALE3 83.50 ▲ 0.76% ITUB4 39.70 ▼ 1.73% BBDC4 17.69 ▼ 0.84% ABEV3 15.69 ▼ 0.51% BBAS3 20.70 ▼ 0.29% B3SA3 16.70 ▼ 1.36% WEGE3 43.13 ▼ 1.35% PRIO3 68.80 ▲ 2.24% SUZB3 41.70 ▼ 2.16% RENT3 42.98 ▼ 2.18% AZZA3 19.05 ▲ 1.06% CSAN3 4.41 ▼ 5.16% RAIZ4 0.45 ▲ 2.27% PCAR3 2.26 ▼ 1.74% GMAT3 4.34 ▲ 1.17% PSSA3 47.92 ▼ 1.60% CVCB3 1.81 ▼ 4.23% POSI3 3.88 ▼ 2.27% SLCE3 17.19 ▼ 0.87% NATU3 9.94 ▲ 1.53% BRKM5 12.21 ▲ 0.49% RANI3 7.85 ▼ 0.25% CSNA3 6.42 ▼ 3.75% CMIN3 4.72 ▼ 1.05% USIM5 9.12 ▼ 7.79% GGBR4 23.34 ▼ 1.02% ENEV3 25.06 ▼ 3.43% NEOE3 33.80 — 0.00% CPFE3 44.52 ▼ 1.53% CMIG4 11.27 ▼ 0.09% EQTL3 38.59 ▼ 0.54% LREN3 13.55 ▼ 1.24% VIVT3 35.52 ▼ 0.20% RAIL3 14.97 ▼ 1.96% KLABIN 16.43 ▼ 2.55% RAIA DROGASIL 19.59 ▼ 0.25% RDOR3 34.84 ▲ 0.26% HAPV3 12.45 ▼ 6.11% FLRY3 15.60 ▼ 2.26% SMTO3 18.25 ▼ 0.82% UGPA3 29.13 ▼ 1.42% VBBR3 33.12 ▼ 0.81% BBSE3 34.12 ▼ 1.04% BPAC11 54.50 ▼ 1.61% CURY3 30.37 ▼ 0.75% AERI3 2.42 ▼ 0.41% VIVARA 22.94 ▼ 0.26% COMPASS 25.90 ▼ 1.89% VAMOS 3.41 ▼ 2.29% SANB11 26.92 ▼ 0.81% ASAI3 8.50 ▼ 1.05% SBSP3 29.03 ▼ 1.66% WALMEX 54.82 ▲ 0.53% GMEXICO 202.10 ▼ 4.45% FEMSA 210.39 ▼ 0.01% CEMEX 21.82 ▼ 3.71% GFNORTE 184.04 ▼ 0.98% BIMBO 59.19 ▲ 0.27% TELEVISA 9.94 ▲ 1.43% AMX 23.13 ▼ 1.11% GAP 413.32 ▼ 1.41% ASUR 296.14 ▼ 1.66% OMA 222.96 ▼ 0.70% KOF 180.84 ▼ 0.13% GRUMA 298.23 ▲ 0.12% KIMBER 38.28 ▼ 0.55% SQM-B 76,590 ▼ 2.06% COPEC 6,145 ▼ 0.08% BSANTANDER 68.99 ▼ 0.16% FALABELLA 5,500 ▲ 1.08% ENELAM 75.75 ▼ 0.89% CENCOSUD 2,060 ▼ 3.06% CMPC 1,055 ▼ 0.94% BANCO CHILE 163.70 ▲ 0.13% LATAM AIR 21.54 ▼ 2.53% YPF 65,000 ▼ 0.46% GGAL 6,060 ▼ 2.02% PAMPA 4,720 ▼ 0.26% TXAR 615.00 ▲ 0.49% ALUAR 940.50 ▼ 0.42% TGS 8,750 ▼ 0.62% CEPU 2,049 ▼ 3.17% MIRGOR 17,225 ▼ 3.23% COME 42.52 ▼ 1.51% LOMA NEGRA 3,105 ▼ 1.82% BYMA 272.25 ▼ 2.77% TELECOM ARG 3,505 ▼ 4.24% ECOPETROL 13.11 ▼ 0.87% BANCOLOMBIA 63.16 ▼ 1.83% GRUPO AVAL 4.01 ▼ 5.20% CREDICORP 316.31 ▼ 3.47% SOUTHERN COPPER 176.78 ▼ 6.22% BUENAVENTURA 34.29 ▼ 7.70% MERCADOLIBRE 1,547 ▼ 3.77% NUBANK 12.19 ▼ 5.72% XP 17.47 ▼ 0.74% PAGSEGURO 8.86 ▼ 1.66% STONE 9.61 ▼ 0.93% GLOBANT 38.87 ▲ 14.06% TECNOGLASS 38.61 ▼ 5.90% GAP AIRPORT 238.45 ▼ 2.15% ASUR 296.14 ▼ 1.66% OMA AIRPORT 102.84 ▼ 1.57% AMX ADR 26.59 ▼ 1.85% FEMSA ADR 121.38 ▼ 0.70% CEMEX ADR 12.56 ▼ 4.60% PETROBRAS ADR 19.93 ▲ 0.76% VALE ADR 16.32 ▼ 1.57% ITAU ADR 7.84 ▼ 3.21% SANTANDER BR 5.34 ▼ 2.11% AMBEV ADR 3.07 — 0.00% CSN 1.26 ▼ 6.67% GERDAU 4.61 ▼ 2.12% LATAM ADR 46.91 ▼ 4.79% BTC 78,181 ▼ 1.12% ETH 2,181 ▼ 1.90% SOL 86.83 ▼ 2.66% XRP 1.42 ▼ 1.25% BNB 657.72 ▼ 2.14% ADA 0.26 ▼ 2.29% DOGE 0.11 ▼ 3.47% AVAX 9.34 ▼ 2.06% LINK 9.75 ▼ 3.13% DOT 1.27 ▼ 3.22% LTC 56.17 ▼ 2.30% BCH 417.55 ▼ 2.10% TRX 0.35 ▲ 0.67% XLM 0.15 ▼ 1.56% HBAR 0.09 ▼ 1.23% NEAR 1.50 ▼ 2.83% ATOM 2.01 ▲ 4.10% AAVE 90.55 ▼ 2.47% SELIC 14.50% EMBRAER 71.25 ▼ 1.76% EMBRAER ADR 55.76 ▼ 5.04% JBS 13.48 ▼ 3.58% JBS BDR 68.50 ▼ 1.72% MBRF3 17.42 — 0.00% MBRFY 3.43 ▼ 2.83% INTER 5.85 ▼ 3.47% EGX 53,155 ▼ 0.49% USD/ZAR 16.68 ▲ 1.37% USD/NGN 1,367 ▼ 0.04% NIKKEI 61,409 ▼ 1.99% CSI300 4,860 ▼ 1.12% HSI 25,963 ▼ 1.62% NIFTY 23,644 ▼ 0.19% KOSPI 7,493 ▼ 6.12% JCI 6,723 ▼ 1.98% USD/JPY 158.73 ▲ 0.24% USD/CNY 6.8087 ▲ 0.36% DAX 23,951 ▼ 2.07% CAC 7,953 ▼ 1.60% FTSE 10,195 ▼ 1.71% MIB 49,116 ▼ 1.87% IBEX 17,623 ▼ 1.05% STOXX 606.92 ▼ 1.48% EUR/USD 1.1631 ▼ 0.34% GBP/USD 1.3324 ▼ 0.58% SPX 7,409 ▼ 1.24% DJI 49,526 ▼ 1.07% NDX 29,125 ▼ 1.54% RUT 2,793 ▼ 2.44% TSX 33,833 ▼ 1.27% VIX 18.43 ▲ 6.78% USD/CAD 1.3749 ▲ 0.24% US10Y 4.5950 ▲ 3.00%
since 2009
Saturday, May 16, 2026

Up to 95% of serious adverse drug events go unreported

By · October 22, 2021 · 4 min read

RIO DE JANEIRO, BRAZIL – Drug reporting systems designed to capture adverse events in the population are notoriously unreliable. With the introduction of Covid vaccines, adverse effects have also become a hot topic, mainly because vaccine injury reporting systems are unreliable.

How common is it for mild, severe, or life-threatening adverse reactions to drugs or vaccines to go unreported? This is an important question because, without reporting, researchers cannot disseminate critical cost-benefit analyses of drugs to the general population.

A 2006 study published in the journal Drug Safety included more than 37 studies from 12 different countries that used various surveillance methods.

Up to 95% of serious adverse drug events go unreported
Up to 95% of serious adverse drug events go unreported. (Photo internet reproduction)

They found evidence of widespread and substantial underreporting of adverse drug reactions (ADRs). These included severe ADRs.

The median underreporting rate in the 37 studies was 94% (82-98%). There was no significant difference between the median underreporting rates calculated for general practice and hospital studies.

Five of the ten general practice studies provided evidence of a higher mean underreporting rate for all ADRs compared with the most severe or severe ADRs (95% and 80%, respectively). In comparison, in five of the eight hospital-based studies, the mean underreporting rate for more severe or severe AMRs remained high (95%).

In 19 studies examining specific drug combinations with severe/serious adverse events, the median under-reporting rate was lower but still high (85%).

This is concerning given that prescription drugs are the third leading cause of death in the U.S. and Europe, after heart disease and cancer.

A 2018 study published in the International Journal of Medical Science Research attempts to answer why this is happening. Again, this is a well-known problem among those who study it, and the data are pretty similar across publications.

The 2018 study found that physicians “know very little about AMR reporting.” They found that 32.8 percent of respondents did not know if the reaction was caused by the drug or that 46.3 percent felt it was unnecessary to report recognized reactions.

Overall, “deficient physician awareness of pharmacovigilance was found,” The researchers emphasized the need to improve physician awareness. Adequate and accessible reporting systems need to be in place to enhance reporting.

WHAT ABOUT VACCINES?

The Vaccine Adverse Event Reporting System (VAERS) of the CDC and FDA is the nationwide early warning system that monitors the safety of vaccines once they are licensed or cleared for use by the FDA.

It is a self-reporting system that does not prove causality but is designed to detect signs of adverse events (e.g., thrombotic events in the COVID-19 vaccine and myocarditis). “VAERS scientists are looking for an unusually high number of adverse event reports following a particular vaccine or a new pattern of adverse events.”

Physicians must report adverse reactions to vaccines to VAERS, but because it is a self-reporting system, it has been criticized because anyone can report a vaccine reaction. The CDC has clarified that a reported event related to vaccine administration does not mean that the vaccine caused the adverse reaction.

Still, it is concerning that VAERS received 2,149 reports of deaths between 1997 and 2013, and no “pattern of concern” was found. But as Senator Ron Johnson wrote on August 22, 2021, there were: “12,791 Covid-19 vaccine-related deaths reported in VAERS over eight months, 16,044 permanent disabilities, 51,242 hospitalizations, and a total of 571,831 adverse events related to Covid-19 vaccines.”

Approximately 17,000 deaths, 25,000 permanent disabilities, and 80,000 hospitalizations related to Covid vaccines have been reported to VAERS in the United States alone.

In a 2011 report titled “Electronic Public Health Support – Vaccine Adverse Event Reporting System (ESP: VAERS),” Harvard medical professors Ross Lazarus, Michael Klompas, and Steve Bernstein report that vaccines are underreported:

Consider that on July 16, 1999, the CDC recommended that health care providers discontinue the use of the approved RotaShield vaccine, a rotavirus vaccine, after only 15 cases of intestinal obstruction were reported to VAERS.

Of course, there is a way for researchers to use VAERS properly. Still, however you look at it, the numbers in VAERS on COVID vaccines are pretty disturbing and staggering. Even though the number of adverse events with vaccines may be minimal, one must consider the number of reports that are probably not related to the vaccine.

The question is how likely it is that a physician will report a suspected adverse effect from the vaccine. If a patient comes in three days after vaccination with some complaint, will most physicians even entertain the idea that the event might be vaccine-related?

Physicians may be biased to believe that severe vaccine injury is infrequent. The CDC claims it is 1 in a million, but how can they claim such a number when there are no proper adverse event reporting systems? Why do they not provide sources or data to support their claim?

It is also important to point out that proper reporting systems are not something that pharmaceutical companies would openly advocate. They have multiple criminal convictions and have falsified information about their drugs, including efficacy. That would be bad for business, and as far as business is concerned, Pfizer has paid one of the highest criminal fines in history.

Read More from The Rio Times

Latin American financial intelligence, daily

Breaking news, market reports, and intelligence briefs — for investors, analysts, and expats.

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.